-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the traditional Chinese medicine system, the new crown belongs to the "warm epidemic", and traditional Chinese medicines
such as clearing heat and detoxification and lung dialysis can be used in the early stage.
According to data from Minai.
com, in 2021, the market size of China's three major terminal markets (see the end of this article for statistical scope) will be close to 23 billion yuan, a slight increase over 2020, but still some distance
from the pre-epidemic level 。
In recent years, the sales of Chinese proprietary Chinese medicines in China's three major terminal markets (: 10,000 yuan)
Source: Minai Grid Bureau database
From the perspective of subdivision terminals, the in-hospital market (public hospitals + public primary medical care) continued to warm up, with 3 star drugs exceeding 1 billion leading the way, exclusive varieties dominating, and windproof Tongsheng granules being named; Retail pharmacies (urban physical pharmacies + online pharmacies) are still under pressure, but with the optimization of epidemic prevention and control policies, it is expected to usher in a reversal
in the future.
The in-hospital market continues to recover, and the exclusive proprietary Chinese medicine dominates
In recent years, the sales of terminal antipyretic and detoxifying proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have fluctuated, and in 2020, affected by the epidemic, the number of hospital diagnoses and treatments declined, the sales of clear heat and detoxification proprietary Chinese medicines declined significantly, and continued to warm up after the normalization of the epidemic, with a year-on-year increase of about 6% in 2021, and continued to grow
slightly in the first half of 2022 。
Sales of terminal heat-clearing and detoxification proprietary Chinese medicines in China's public medical institutions in recent years (: 10,000 yuan)
Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions
In 2021, the total market share of the TOP20 proprietary Chinese medicine products in China's public medical institutions exceeded 70%, and exclusive varieties (including exclusive dosage forms) accounted for more than 50%; In terms of sales, 3 star drugs with more than 1 billion led the way, namely Xiyanping injection (2.
3 billion +), Pudi blue anti-inflammatory oral liquid (2.
1 billion +) and Yan Suning for injection (1 billion +).
Among the 20 products, 5 are injections, among which Xiyanping injection (Jiangxi Qingfeng Pharmaceutical), Xuebijing injection (Tianjin Hongri Pharmaceutical), and Retoxinning injection (Jiangsu Kangyuan Pharmaceutical) have been included in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia" issued by the National Health Commission for many times, and are recommended for patients with severe (gas camp two burnt evidence) or critical (internal closure and external decertification
).
。
In 2021, China's public medical institutions terminal clear heat and detoxification Chinese proprietary medicine TOP20 products
Source: Minainet Comprehensive Database
Eight proprietary Chinese medicines surged by more than 10%, of which 6 were exclusive varieties (including exclusive dosage forms), including Xiyanping injection from Jiangxi Qingfeng Pharmaceutical (20.
55%), Pudi Blue Anti-inflammatory Oral Liquid from Jichuan Pharmaceutical (15.
9%), Tianjin Hongri Pharmaceutical's Xuebijing Injection (22.
04%), Anhui Jiuhuahuayuan Pharmaceutical's Bairui Granules (24.
6%), Jiangxi Puzheng Pharmaceutical's Topless Purple Pearl Granules (30.
1%) and Shandong Runzhong Pharmaceutical's Windproof Tongsheng Granules (21.
4%)
。
Relying on the exclusive variety of Xiyanping injection, Jiangxi Qingfeng Pharmaceutical has "dominated" the market
of Chinese proprietary Chinese medicine for heat and detoxification for many years.
Xiyanping injection is a national medical insurance Class B variety, with the effect of clearing heat and detoxification, cough and diarrhea, suitable for bronchitis, tonsillitis, bacterial dysentery, etc.
, in 2021, the terminal sales of China's public medical institutions exceeded 2.
3 billion yuan, a year-on-year increase of 20.
55%.
The windproof Tongsheng granules of Shandong Run Traditional Chinese Medicine are national medical insurance class A, basic drugs, OTC class A (double-span) varieties, which have the effect of detoxifying the surface and tongli, clearing heat and detoxification, and are suitable for external cold and internal heat, solid surface, cold and strong heat, headache and dry throat, short urine, constipation, rubella and eczema
.
According to data from Minai.
com, the sales growth rate of terminal windproof tongsheng granules in China's public medical institutions reached 21.
4% in 2021, up 4 places from 2020
.
It is worth mentioning that this product is a recommended drug
in the "Guidelines for Home Medicine Intervention for People with New Coronavirus Infection" released recently.
The out-of-hospital market is still under pressure, and more than 1 billion varieties "fall"
During the epidemic, the sales of "four types of drugs" in physical pharmacies were greatly restricted, and even banned and removed from the shelves, and various places have issued a catalog of "four types of drugs", and some antipyretic and detoxifying proprietary Chinese medicines are also among them
.
Before the outbreak of the epidemic, the sales scale of Chinese proprietary Chinese medicines for clearing heat and detoxification at China's retail pharmacy terminals (urban physical pharmacies + online pharmacies) increased year by year, and began to decline in 2020, and the decline increased
in 2021.
From the perspective of market segmentation, urban physical pharmacies have been greatly affected, but with the optimization of epidemic prevention and control policies, it is expected to usher in a reversal in the future; Although the base of online pharmacies is small, the volume is obvious, and there has been double-digit growth
in the past two years.
Sales of Chinese proprietary Chinese medicines in recent years (10,000 yuan) in China's retail pharmacies;
Source: Minai Grid Bureau database
From the perspective of product ranking, 19 of the top 20 products in 2021 had sales of more than 100 million yuan, and Banlangen granules ranked first for many consecutive years, with sales exceeding 1.
4 billion yuan in 2020 and declining in 2021; Pudi Blue Anti-inflammatory Tablets ranked second, and Pudi Blue Anti-inflammatory Oral Liquid ranked third, up 1 place
from 2020.
2021 Top 20 products of Chinese proprietary Chinese medicine in Chinese retail pharmacy terminals
Note: Less than 100 million yuan is represented by *
Source: Minainet Comprehensive Database
Four proprietary Chinese medicines surged by more than 10%, of which two were exclusive varieties (including exclusive dosage forms), namely Jichuan Pharmaceutical's Pudi Blue Anti-inflammatory Oral Liquid (13.
89%) and Guizhou Bailing's compound yellow flower spray (26.
6%)
.
Compound Goldenrod Spray is the only spray among the 20 products on the list, which is an OTC A variety, which has the effect of clearing heat and detoxification, dispersing wind heat, and clearing throat, and is suitable for upper respiratory tract infections, acute and chronic pharyngitis, mouth and tongue sores, swollen gums, bad breath, etc
.
In recent years, the sales of compound goldenrod spray in China's retail pharmacy terminals have increased year by year, with double-digit growth rates, exceeding 100 million yuan
for the first time in 2021.
Sales of compound goldenrod spray in China's retail pharmacies in recent years (: million yuan)
Source: Minai Grid Bureau database
Qingkailing granules are national medical insurance class A, OTC class A (double-span) varieties, with the effect of clearing heat and detoxification, calming and calming the spirit, and are recommended drugs in the "Guidelines for Home Chinese Medicine Intervention for Patients Infected with New Coronavirus Infection", and the symptoms are obvious sore throat, fever, muscle aches, fatigue or cough
.
From the perspective of manufacturers, Guangyao Baiyunshan, Correction Pharmaceutical, and Yunnan Baiyao all occupy a dominant position in a number of products on the list, among which Guangyao Baiyunshan dominates the market
in three products: Banlangen granules, compound Banlangen granules and Qingkailing granules.
Source: Minainet database
Note: Minai.
com's "Drug Competition Pattern of China's Three Major Terminal and 6 Major Markets", the statistical scope is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
